IP Library Granted Patent US 10,589,072
Granted Patent B2
US 10,589,072 · App. 16/029,319 · Granted Mar 17, 2020

Methods for treating sinus diseases

Inventors: Stephen W. Chandler (Montgomery, AL); David W. Sanso (Morrison, CO)
Assignee: BioVision Technologies, LLC
A61M25/10182A61B1/00135A61B1/015A61B1/0623A61B1/233A61B17/24A61M15/08A61M16/0434A61M16/0461A61M25/1002A61M25/1011A61M31/00A61M2025/1052A61M2202/048A61M2205/8206A61M2210/06A61M2210/0681
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,589,072
App. No.
16/029,319
Granted
Mar 17, 2020
Kind
B2
Abstract

Methods and devices to quickly and accurately apply medication to a paranasal sinus are disclosed. Additionally, the methods and devices prevent the medication applied to a paranasal sinus from flowing down a patient's throat by expanding, using an inflation lumen of a device, an expandable member of the device adjacent to the patient's choana.

Claims (24)

1. A method for treating a sinus disease, the method comprising the steps of:

(a) inserting a portion of a device into a nasal cavity of a patient through a nostril, the device comprising:

a handle comprising a proximal end and a distal end;

an inflation device at least partially disposed within the handle;

a flexible tubular member extending from the handle, the flexible tubular member comprising an inflation lumen fluidly coupled to the inflation device, and a second lumen fluidly coupled to a medication port; and

an expandable member attached to the flexible tubular member, the expandable member comprising a proximal end and a distal end, wherein the inflation lumen opens, via an inflation port, into the expandable member, wherein the medication port is disposed proximally of the proximal end of the expandable member;

(b) expanding, using the inflation lumen, the expandable member adjacent to the patient's choana;

(c) introducing an amount of medication into the nasal cavity, such that at least a portion of the medication enters an ostium of a paranasal sinus of the patient and enters the paranasal sinus and at least a portion of the medication remains in the paranasal sinus for a period of 5 minutes to 40 minutes.

2. The method of claim 1 , wherein the device further comprises an illumination device disposed adjacent a distal end of the flexible tubular member and distally of the expandable member.

3. The method of claim 2 , further comprising the step of activating the illumination device.

4. The method of claim 3 , further comprising the step of viewing light emitted from the illumination device through a portion of the patient's soft palate.

5. The method of claim 1 , wherein the device further comprises a stabilizer slidably coupled to the flexible tubular member, and wherein the stabilizer is capable of sliding along the flexible tubular member between the handle and the expandable member.

6. The method of claim 5 , further comprising the step of sliding the stabilizer toward and/or away from the patient's nose when the portion of the device is inserted in the nasal cavity.

7. The method of claim 1 , further comprising the step of removing at least a portion of the medication through the medication port in the flexible tubular member.

8. The method of claim 1 , further comprising the step of inserting the device into a second portion of the nasal cavity of the patient through a second nostril and performing steps (b) through (e).

9. The method of claim 1 , wherein the level of medication is maintained for 10 minutes to 30 minutes.

10. The method of claim 9 , wherein the level of medication is maintained for 15 minutes to 25 minutes.

11. The method of claim 10 , wherein the level of medication is maintained for at least 20 minutes.

12. The method of claim 1 , wherein the amount of the medication introduced to the nasal cavity is between 2 milliliters to 250 milliliters.

13. The method of claim 12 , wherein the amount of the medication introduced to the nasal cavity is between 50 milliliters to 200 milliliters.

14. The method of claim 13 , wherein the amount of the medication introduced to the nasal cavity is between 100 milliliters to 150 milliliters.

15. The method of claim 1 , wherein the step of expanding the expandable member adjacent to the patient's choana comprises placing the expandable member in the patient's nasopharynx.

16. The method of claim 1 , further comprising the step of collapsing the expandable member.

17. The method of claim 16 , further comprising the step of removing the device from the nasal cavity.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2025
From: BIOVISION TECHNOLOGIES LLC
To: BIOVISION HOLDINGS LLC
Reel/Frame 071171/0030 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2024
From: CHANDLER, STEPHEN
To: VALENT MEDICAL, INC.
Reel/Frame 068796/0831 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2024
From: SANSO, DAVID
To: VALENT MEDICAL, INC.
Reel/Frame 068797/0028 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2024
From: BIOVISION HOLDINGS, LLC
To: VALENT MEDICAL, INC.
Reel/Frame 068799/0583 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2018
From: CHANDLER, STEPHEN W.; SANSO, DAVID
To: BIOVISION TECHNOLOGIES, LLC
Reel/Frame 046297/0696 →
Continuity (7)
Continuation 15166102 · May 26, 2016
Continuation In Part 14699999 · Apr 29, 2015
Continuation In Part 14572353 · Dec 16, 2014
Continuation In Part 14298521 · Jun 6, 2014
Provisional Application 62168505 · May 29, 2015
Provisional Application 61917097 · Dec 17, 2013
Related Publication 20190091450A1 · Mar 28, 2019
Cited By (1)
US 12,458,784